Evidence for benefits of angiotensin receptor blockade beyond blood pressure control (Q30446535)

21 June 2017

1 reference

title

Evidence for benefits of angiotensin receptor blockade beyond blood pressure control (English)

1 reference

21 June 2017

Helmy M Siragy

1

1 reference

PubMed ID

18625154

21 June 2017

language of work or name

1 reference

1 August 2008

1 reference

Current Hypertension Reports

21 June 2017

1 reference

21 June 2017

10

1 reference

21 June 2017

4

1 reference

21 June 2017

261-267

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-008-0050-x

21 June 2017

0 references

cites work

Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-008-0050-X

Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-008-0050-X

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

12 December 2020

Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication

1 reference

12 December 2020

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

12 December 2020

Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor

1 reference

12 December 2020

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

12 December 2020

Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade

1 reference

12 December 2020

Angiotensin AT1 and AT2 receptors--the battle for health and disease

1 reference

12 December 2020

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study

1 reference

12 December 2020

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

1 reference

12 December 2020

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress

1 reference

12 December 2020

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial

1 reference

12 December 2020

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

12 December 2020

The renin angiotensin system as a therapeutic target to prevent diabetes and its complications

1 reference

12 December 2020

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

12 December 2020

Preventing microalbuminuria in type 2 diabetes

1 reference

12 December 2020

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

12 December 2020

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

12 December 2020

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

12 December 2020

Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients

1 reference

12 December 2020

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

1 reference

12 December 2020

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

12 December 2020

Regression of left ventricular hypertrophy in human hypertension with irbesartan.

1 reference

12 December 2020

Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers

1 reference

12 December 2020

Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice

1 reference

12 December 2020

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

1 reference

12 December 2020

The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats

1 reference

12 December 2020

Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients

1 reference

12 December 2020

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

1 reference

12 December 2020

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

12 December 2020

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

1 reference

12 December 2020

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

12 December 2020

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

12 December 2020

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

1 reference

12 December 2020

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

12 December 2020

Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation

1 reference

12 December 2020

10.1007/S11906-008-0050-X

Identifiers

DOI

1 reference

PubMed ID

18625154

Dimensions Publication ID

21 June 2017

0 references

1 reference

PubMed ID

18625154